Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + butalbital + caffeine
- Development stage
- Approved
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspirin + butalbital + caffeine is an oral combination medication used primarily for the acute treatment of tension (muscle contraction) headaches. It consists of three active ingredients: **aspirin** (a nonsteroidal anti-inflammatory drug and analgesic that reduces inflammation and pain by inhibiting cyclooxygenase enzymes), **butalbital** (a barbiturate that exerts central nervous system depressant effects, including muscle relaxation and sedation), and **caffeine** (a CNS stimulant and adenosine antagonist that enhances the analgesic effects and may cause cerebral vasoconstriction). The combination is prescribed for short-term management only because of the risk of dependence associated with butalbital and the risk of rebound (medication overuse) headaches with chronic use. It is a Schedule III controlled substance in the United States due to abuse potential[1][2][6][7].
- Brand names
- FiorinalFiormorFiortalFortabsButalbital CompoundIdenalLaniroif
- Other names
- aspirin, butalbital, and caffeine
02
Targets
ADORA2B (Adenosine A2B receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GABRR (GABA-A receptor subunit rho)PGHS-1 (Prostaglandin G/H Synthase 1)ADORA3 (Adenosine A3 receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on aspirin + butalbital + caffeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + butalbital + caffeine.